Skip to main content
Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma

Fig. 7

Expression of HIF1α and HIF2α in ccRCC tumor tissues versus in the associated normal tissues: The expression level of HIF1α (A) or HIF2α (C) across TCGA-RCC subtypes in renal tumor (red) versus the associated normal renal tissues (blue) were box-plotted. The expression of HIF1α (B) or HIF2α (D) among different stages of ccRCC tumor tissues versus the associated normal tissues was box-plotted. The expression of HIF1α or HIF2α was presented in the log2 (TPM + 1) scale format. Data were presented as the mean ± SD. A t-test was used to evaluate the statistical significance of the mRNA expression level in normal renal tissues versus tumor tissues. One-way ANOVA was used to compare HIF1α expression or HIF2α expression among normal renal tissues versus different stages of ccRCC tumor tissues. The figure was performed using R version 4.0.3

Back to article page